2. Immunology/Inflammation Apoptosis Cytoskeleton
  3. Interleukin Related Apoptosis Caspase Cadherin
  4. Tralokinumab

Tralokinumab  (Synonyms: CAT354)

Cat. No.: HY-P99053 Purity: 99.12%
COA
SDS
Technical Support

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.

For research use only. We do not sell to patients.

CAS No. : 1044515-88-9

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Tralokinumab Featured Recommendations:

Tralokinumab Related Antibodies

Top Publications Citing Use of Products
Cell Imaging/Staining
IF

    Tralokinumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    Representative images of fibrosis-induced spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.

    Tralokinumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373.  [Abstract]

    Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.

    View All Interleukin Related Isoform Specific Products:

    View All Isoforms
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    View All Caspase Isoform Specific Products:

    View All Isoforms
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2].

    Isotype

    Human IgG4 lambda
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target[1]

    IL-13

     

    In Vivo

    Tralokinumab (3 mg/kg; intraperitoneal injection; once every other day; from day 35 to day 63) can inhibit pulmonary fibrosis and reduce epithelial cell apoptosis in a humanized SCID mouse model of pulmonary fibrosis[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female C.B-17-scid-beige (C.B-17SCID/bg) mice received single-cell preparations of IPF and normal fibroblasts via tail vein injection[2]
    Dosage: 3 mg/kg
    Administration: Intraperitoneal injection; once every other day; from day 35 to day 63
    Result: Blocked aberrant lung remodeling, promoted lung repair and restored epithelial integrity.
    Significantly decreased fibrotic alterations.
    Reduced serum CC16 (a marker of epithelial injury) and reduced BAL caspase 3 activity.
    Enhanced the expression of epithelial-associated genes, including E-cadherin and all of the surfactants.
    Clinical Trial
    Gene ID

    3596  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    144.14 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Tralokinumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 lambda
    Biological Activity
    • Tralokinumab (HY-P99053) neutralizes Recombinant Human IL-13 (HY-P70568) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.6630 μg/mL in the presence of 10 ng/mL Recombinant Human IL-13.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tralokinumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tralokinumab1044515-88-9CAT354CAT 354CAT-354Interleukin RelatedApoptosisCaspaseCadherinILIgG4 monoclonal antibodyIL-13atopic dermatitispulmonary fibrosis modelInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tralokinumab
    Cat. No.:
    HY-P99053
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.